Evodiamine inhibits 12-O-tetradecanoylphorbol-13-acetate-induced activator protein 1 transactivation and cell transformation in human hepatocytes

Phytotherapy Research

Volumn 25, Issue 7, 2011, Pages 1018-1023

  Chao, De Cheng ^a   Lin, Li Jen ^a   Hsiang, Chien Yun ^a   Li, Chia Cheng ^a   Lo, Hsin Yi ^a   Liang, Ji An ^b   Kao, Shung Te ^a   Wu, Shih Lu ^a   Ho, Tin Yun ^a  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

12 O tetradecanoylphorbol 13 acetate; Activator protein 1; Chinese herb; Evodiamine; Hepatocellular carcinoma; Transformation

Indexed keywords

ANTINEOPLASTIC AGENT; EVODIA RUTAECARPA EXTRACT; EVODIAMINE; MITOGEN ACTIVATED PROTEIN KINASE; PHORBOL 13 ACETATE 12 MYRISTATE; PLANT EXTRACT; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL TRANSFORMATION; COLONY FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; ENZYME PHOSPHORYLATION; EVODIA; EVODIA RUTAECARPA; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL; PROTEIN FUNCTION; REPORTER GENE; TRANSACTIVATION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE; CELL TRANSFORMATION, NEOPLASTIC; EVODIA; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HEPATOCYTES; HUMANS; PHOSPHORYLATION; PLANT EXTRACTS; QUINAZOLINES; TETRADECANOYLPHORBOL ACETATE; TRANSCRIPTION FACTOR AP-1; TRANSCRIPTIONAL ACTIVATION; TRANSFECTION;

EVODIA RUTAECARPA;

EID: 84860394995     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.3392     Document Type: Article

References (31)

1. Angel P, Karin M. 1991. The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim Biophys Acta 1072:129-157. (Pubitemid 121007534)
2. Cheng WY, Hsiang CY, Bau DT et al. 2007. Microarray analysis of vanillin-regulated gene expression profile in human hepatocarcinoma cells. Pharmacol Res 56:474-482.
3. Chiou WF, Chou CJ, Shum AY, Chen CF. 1992. The vasorelaxant effect of evodiamine in rat isolated mesenteric arteries: mode of action. Eur J Pharmacol 215:277-283.
4. Chiou WF, Liao JF, Chen CF. 1996. Comparative study of the vasodilatory effects of three quinazoline alkaloids isolated from Evodia rutaecarpa. J Nat Prod 59:374-378.
5. Dong Z, Birrer MJ, Watts RG, Matrisian LM, Colburn NH. 1994. Blocking of tumor promoter-induced AP-1 activity inhibits induced transformation in JB6 mouse epidermal cells. Proc Natl Acad Sci USA 91:609-613. (Pubitemid 24041451)
6. Donovan JC, Milic A, Slingerland JM. 2001. Constitutive MEK/MAPK activation leads to p27 (Kip1) deregulation and antiestrogen resistance in human breast cancer cells. J Biol Chem 276:40888-40895.
7. Dumont JA, Bitonti AJ, Wallace CD, Baumann RJ, Cashman EA, Cross-Doersen DE. 1996. Progression of MCF-7 breast cancer cells to antiestrogen-resistant phenotype is accompanied by elevated levels of AP-1 DNA-binding activity. Cell Growth Differ 7:351-359. (Pubitemid 26360774)
8. Fukazawa H, Mizuno S, Uehara Y. 1995. A microplate assay for quantitation of anchorage-independent growth of transformed cells. Anal Biochem 228:83-90.
9. Giannelli G, Antonaci S. 2006. Novel concepts in hepatocellular carcinoma: from molecular research to clinical practice. J Clin Gastroenterol 40:842-846. (Pubitemid 44506930)
10. Hsiang CY, Lai IL, Chao DC, Ho TY. 2002. Differential regulation of activator protein 1 activity by glycyrrhizin. Life Sci 70:1643-1656.
11. Hsiang CY, Wu SL, Ho TY. 2004. Activation of activator protein 1 and extracellular signal-regulated kinases in human hepatocellular transformation. Tumour Biol 25:313-320.
12. Karin M, Liu Z, Zandi E. 1997. AP-1 function and regulation. Curr Opin Cell Biol 9:240-246. (Pubitemid 27135992)
13. Ko HC, Wang YH, Liou KT et al. 2007. Anti-inflammatory effects and mechanisms of the ethanol extract of Evodia rutaecarpa and its bioactive components on neutrophils and microglial cells. Eur J Pharmacol 555:211-217.
14. Lamb RF, Hennigan RF, Turnbull K et al. 1997. AP-1-mediated invasion requires increased expression of the hyaluronan receptor CD44. Mol Cell Biol 17:963-976. (Pubitemid 27044395)
15. Li SC. 1596. 1976. Pen-tsao Kang Mu. National Researcher Institute of Chinese Medicine: Taipei.
16. Matsuda H, Yoshikawa M, Iinuma M, Kubo M. 1998. Antinociceptive and anti-inflammatory activities of limonin isolated from the fruits of Evodia rutaecarpa var. bodinieri. Planta Med 64:339-342. (Pubitemid 28234272)
17. Ogasawara M, Matsubara T, Suzuki H. 2001. Inhibitory effects of evodiamine on in vitro invasion and experimental lung metastasis of murine colon cancer cells. Biol Pharm Bull 24:917-920. (Pubitemid 32750318)
18. Ogasawara M, Matsunaga T, Takahashi S, Saiki I, Suzuki H. 2002. Anti-invasive and metastatic activities of evodiamine. Biol Pharm Bull 25:1491-1493. (Pubitemid 39663174)
19. Ogasawara M, Suzuki H. 2004. Inhibition by evodiamine of hepatocyte growth factor-induced invasion and migration of tumor cells. Biol Pharm Bull 27:578-582. (Pubitemid 41701850)
20. Parkin DM. 2001. Global cancer statistics in the year 2000. Lancet Oncol 2:533-543. (Pubitemid 33586866)
21. Pharmacopoeia Commission of People's Republic of China (ChPC). 2000. In Pharmacopoeia of People's Republic of China, Vol. 1. Chemical Industry Press: Beijing; 118-119.
22. Pinkus R, Weiner LM, Daniel V. 1996. Role of oxidants and antioxidants in the induction of AP-1, NF-kappaB, and glutathione S-transferase gene expression. J Biol Chem 271:13422-13429. (Pubitemid 26185383)
23. Risse-Hackl G, Adamkiewicz J, Wimmel A, Schuermann M. 1998. Transition from SCLC to NSCLC phenotype is accompanied by an increased TRE-binding activity and recruitment of specific AP-1 proteins. Oncogene 16:3057-3068. (Pubitemid 28297728)
24. Saez E, Rutberg SE, Mueller E et al. 1995. c-fos is required for malignant progression of skin tumors. Cell 82:721-732.
25. Sawai H, Okazaki T, Yamamoto H et al. 1995. Requirement of AP-1 forceramide-induced apoptosis in human leukemia HL-60 cells. J Biol Chem 270:27326-27331.
26. Schmidt CM, McKillop IH, Cahill PA, Sitzmann JV. 1997. Increased MAPK expression and activity in primary human hepatocellular carcinoma. Biochem Biophys Res Commun 236:54-58. (Pubitemid 27341838)
27. Shaulian E, Karin M. 2001. AP-1 in cell proliferation and survival. Oncogene 20:2390-2400. (Pubitemid 32531297)
28. Shin YW, Bae EA, Cai XF, Lee JJ, Kim DH. 2007. In vitro and in vivo antiallergic effect of the fructus of Evodia rutaecarpa and its constituents. Biol Pharm Bull 30:197-199. (Pubitemid 46066347)
29. Shyu KG, Lin S, Lee CC et al. 2006. Evodiamine inhibits in vitro angiogenesis: Implication for antitumorgenicity. Life Sci 78:2234-2243.
30. Trosko JE. 2001. Commentary: is the concept of'tumor promotion' a useful paradigm? Mol Carcinog 30:131-137.
31. Wu CL, Hung CR, Chang FY, Lin LC, Pau KY, Wang PS. 2002. Effects of evodiamine on gastrointestinal motility in male rats. Eur J Pharmacol 457:169-176. (Pubitemid 35447659)